What is the price of arch Therapeutics stock?
One share of ARTH stock can currently be purchased for approximately $0.09. How much money does Arch Therapeutics make? Arch Therapeutics has a market capitalization of $21.33 million.
Where can I buy Arth shares?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Will arch Therapeutics (Arth) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote “Outperform” if you believe ARTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
See more
How has Arch Therapeutics' stock performed in 2022?
Arch Therapeutics' stock was trading at $0.0950 at the start of the year. Since then, ARTH shares have decreased by 51.6% and is now trading at $0....
How were Arch Therapeutics' earnings last quarter?
Arch Therapeutics, Inc. (OTCMKTS:ARTH) released its earnings results on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings p...
Who are Arch Therapeutics' key executives?
Arch Therapeutics' management team includes the following people: Dr. Terrence W. Norchi M.D. , Co-Founder, Chairman, Pres, CEO & Sec. (Age 57,...
Who are some of Arch Therapeutics' key competitors?
Some companies that are related to Arch Therapeutics include GlucoTrack (GCTK) , Integrity Applications (IGAP) , Isoray (ISR) , Isoray (ISR) ,...
What other stocks do shareholders of Arch Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Scienc...
What is Arch Therapeutics' stock symbol?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How do I buy shares of Arch Therapeutics?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
What is Arch Therapeutics' stock price today?
One share of ARTH stock can currently be purchased for approximately $0.05.
How much money does Arch Therapeutics make?
Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $10.91 million and generates $10 thousand in revenue each year.
When will Arch Therapeutics release its earnings?
What is the ticker symbol for Arch Therapeutics?
Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, July 22nd 2021. View our earnings forecast for Arch Therapeutics.
What is the official website of Arch Therapeutics?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
What is Arch Therapeutics?
The official website for Arch Therapeutics is www.archtherapeutics.com.
Does Arch Therapeutics pay dividends?
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
About ARTH
Arch Therapeutics does not currently pay a dividend.
Analyst Forecast
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
News
According to 7 analysts, the average rating for ARTH stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 2,960.00% from the latest price.
How long are futures trading delayed?
AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication AC5® Advanced Wound System demonstrated notable imp...
How often do exchanges report short interest?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet
When are actual numbers added to the table?
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Does Arth pay dividends?
Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Source: Kantar Media
Signals & Forecast
ARTH is not currently paying a regular dividend.
Support, Risk & Stop-loss
The Arch Therapeutics Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Arch Therapeutics Inc stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $0.10 and $0.10. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Arch Therapeutics Inc finds support just below today's level at $0.10.
Insiders are very positive buying more shares than they are selling in Arch Therapeutics Inc
Arch Therapeutics Inc holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Arch Therapeutics Inc
In the last 62 trades there were 22.8 million shares bought and 30 thousand shares sold. The last trade was done 51 days ago by Fish Guy L. who bough 250 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
